AB Research & Media

I'm helping C-level executives and investors, as well as B2B companies in life sciences to stand out from the noise. 

In just one year, I've successfully delivered dozens of content projects for various clients, including life science-focused venture capital funds, a number of clinical stage publicly traded companies, and various chemical and biotech startups and larger organizations. 

Reach out here or via www.AndriiBuvailo.com to schedule a 30 min exploratory call.

Science & Tech Communicator, Ghostwriter

BiopharmaTrend.com

Your go-to resource for news, trends, and analysis of the cutting-edge advances in pharma, biotech and healthcare.

Reach out for sponsorship opportunities: info@biopharmatrend.com

Co-Founder, Advisor 

Enamine Ltd.

Head Of Digital Marketing

Together with our great team we conceptualized and developed a major part of www.EnamineStore.com, the world's largest e-shop of fine chemicals for drug discovery, and implemented a number of digital marketing initiatives. 

Over several years, we managed to grow this channel from insignificant project in the overall structure of the company's global revenue to a strategically significant % (online + buyer-vendor integrations). 

I also supervised punch-out and API integrations with most strategic buyers and smaller customers. 

Finally, under my supervision, we created a small department of digital marketing, which I then headed. We built Enamine's LinkedIn presence from ground-up to 13k followers and I was directing the major update of the company main website www.enamine.net from old "business-card" version into a multifunctional digital asset.

Director Of Ecommerce

Digital Marketing Manager

Forbes Technology Council

Published 3 articles and 10 small thought leadership contributions on Forbes.com.

Contributing Writer

YUNASKO

YUNASKO-Ukraine is an R&D company developing technology for producing highly powerful ultracapacitors. During its life, the company manufactured prototypes of the most powerful ultracapacitors on the market, elaborated design solutions for such prototypes and grew intellectual property portfolio, which included several Ukrainian, European, French, Latvian, USA and international patent applications.

Director

Project Management and Administration
Intellectual Property Management
Supercapacitor Research
Research Consultancy (Chemistry and Material Science)

Research Engineer / Intellectual Property Coordinator

Temple University

I spent a year in The Borguet Group at Temple University. Responsibilities included research work in the field of gas sensor technology research and development; supervising research work by undergraduate students, preparation of research papers for publication; preparation of presentations in PowerPoint, giving talks on the subject at conferences and research meetings; establishment of collaborative connections.

Research Scholar 

#1 Most Followed Voice in AI Business (1.5M) | Leading AI Entrepreneur & Advisor | Former Amazon, IBM | LinkedIn Top Voice | @alliekmiller on Instagram, X, TikTok

Former scientist. Tech and business writer/editor, published on Forbes.

Co-founder @ www.BiopharmaTrend.com. 

IT management experience, B2B e-commerce supervision in a global chemical company 
Executive and entrepreneurial experience managing startups and consulting agencies. Gen AI and prompt engineering expert. 

A former researcher used to work in Ukraine/United States/Germany/Belgium (coordination/bioinorganic chemistry; nanotech; sensors and biosensors, materials and surface science). PhD in Physical Chemistry. 

Personal website: https://www.andriibuvailo.com

WOW, Eli Lilly and Company becomes first healthcare firm to hit $1 trillion market cap... let that sink in.

Andrii Buvailo, Ph.D.

Science & Tech Communicator | AI & Digital | Life Sciences | Chemistry

📊 Can quantum-powered optimization beat generative AI in designing new drug candidates?  

That’s the question tackled in a new paper by Kendall Byler and Shahar Keinan from PolarisQB (Thank you for bringing this to my attention, Shahar! Link in the comments 👇). 

Rather than comparing quantum computing and AI as broad technologies, the study puts two structure-based drug design (SBDD) platforms head-to-head:

⚙️ QuADD, which uses quantum annealing to optimize fragment-based molecular design

⚙️ BInD, a deep generative diffusion model that builds molecules and their protein interactions from scratch using AI

Both methods were tested on the same drug target, thrombin, a key enzyme involved in blood clotting. The idea was to see which platform produces more viable drug-like molecules in terms of binding affinity, drug-likeness, interaction fidelity, and synthetic feasibility.

💡 After generating and analyzing over 3,600 candidate molecules from each platform, the results showed clear performance differences:

- QuADD molecules had consistently stronger predicted binding affinities and better replication of key hydrogen bonds (notably with Ser214 and Gly216)

- BInD outputs were more structurally diverse, but often fell short in drug-likeness (e.g., low TPSA, high synthetic complexity)

- QuADD ran 80× faster (~30 minutes vs. 40 hours), producing drug-like candidates with lower synthetic complexity scores, making them more realistic for follow-up synthesis

In short, while BInD explores a broader chemical space, QuADD delivers more viable, synthesizable, and pharmacologically relevant candidates, so I think the results highlight the promise of quantum-optimized search in early-stage drug discovery. But also, I think there is clear complementarity between methods... 

What do you think?

Why does Europe’s path to biotech success look so different from the U.S. model?

Just co-authored a new deep-dive with Andrii Lozoniuk on why Europe’s life science momentum may finally be shifting from “potential” to something more durable — and the timing feels right.

Across the continent, we’re seeing concrete signals:

💡 €308M Series C for Tubulis GmbH, the largest private ADC raise globally.

💡 New funds from Sofinnova Partners (€650M) and Medicxi (€500M) in the same quarter.

💡 Belgium preparing to add 1,500 biotech workers per year, while countries like Lithuania already derive ~3% of GDP from life sciences... etc. 

Of course, the fate of European biotech will be shaped by its major hubs — the UK, Switzerland, Denmark, France, the Netherlands, Belgium. 

But what struck me while working on this piece is how even emerging regions are starting to produce real signals of quality: Lithuania’s CRISPR and microfluidics ecosystem (e.g., Caszyme, Atrandi Biosciences), Prague’s growing Prague.bio cluster, or Latvia’s Cellbox Labs raising €3.3M non-dilutive for organ-on-chip tech. These aren’t the center of the story, but they are useful indicators of how broad the base of talent and innovation has quietly become.

We also address the challenges: early-stage capital is still tight, and fragmentation across 27 legal systems creates real friction. That’s why structural ideas like EU-INC — the proposed EU-wide corporate form now being shaped for a March 2026 proposal — look timely and promising.

Europe isn’t the easiest place to scale biotech, but it’s becoming one of the most sustainable places to build it long-term. 

Link to the article: https://lnkd.in/dDY7_4fK 

Image credit: Philip Hemme, Flot.bio (with permission).

Andrii Buvailo

Tech and business writer/editor, published on Forbes; content strategy.

Technology scout, the life sciences industry.

Co-founder @ www.BiopharmaTrend.com, and Deep Pharma Intelligence (exit)

Write weekly newsletter: "Where Technology Meets Biology" 
https://www.linkedin.com/newsletters/where-technology-meets-biology-6887116540035022848/

Substack newsletter "Where Tech Meets Bio" (www.techlifesci.com)

IT management experience, B2B e-commerce supervision in a global chemical company 

Executive and entrepreneurial experience managing startups and consulting agencies

A former researcher used to work in Ukraine/United States/Germany/Belgium (coordination/bioinorganic chemistry; nanotech; sensors and biosensors). PhD in Physical Chemistry. 

Personal website: https://www.andriibuvailo.com

Helping molecules become drugs 💊 @ LIOS

Tubulis GmbH

Sofinnova Partners

Medicxi

Caszyme

Atrandi Biosciences

Prague.bio

Cellbox Labs

Founder & CEO @ Flot.bio

Flot.bio

BREAKING NEWS: Johnson & Johnson bets $3 billion on bifunctional small molecule for oncology 💊 

Johnson & Johnson announced today it will acquire Halda Therapeutics for $3.05B in cash, adding a novel class of bifunctional small molecules, RIPTACs™, to its oncology pipeline.

Halda’s lead candidate, HLD-0915, is a first-in-class, orally available RIPTAC therapeutic in Phase 1/2 for metastatic castration-resistant prostate cancer (mCRPC). The molecule functions via an induced proximity mechanism, holding together the androgen receptor (AR) and BRD4, disrupting BRD4 activity selectively in tumor cells. 

This represents a chemically precise “hold and kill” approach with promising early clinical efficacy and tolerability.

The RIPTAC platform is designed to overcome common resistance mechanisms in targeted cancer therapies by creating ternary complexes that drive selective degradation or inactivation of intracellular proteins—opening the door to a new therapeutic class beyond conventional inhibitors or degraders.

Founded in 2019, Halda is based in New Haven, CT, and backed by leading life science investors including RA Capital, Vida Ventures, and Taiho Ventures.

Another reason why I think chemical modalities are on the rise! 🧪 

Image credit: GlobeNewswire

A shout-out to the latest Where Tech Meets Bio deep dive that unpacked a lot around Protein Language Models (PLMs) — what they are, who’s building them, and where pharma is already putting them to use.

There is a certain analogy between proteins and human language: amino acid sequences are kind of like sentences, local context matters, but so do long-range dependencies and distant structural features, interactions between moieties, etc.  

That's why PLMs are a hot niche right now. In PLMs, scientists use various architectures and algorithms, taking inspiration from classical language models. For instance, transformer models from NLP to learn the “grammar” of proteins directly from massive sequence datasets, enabling structure prediction, function annotation, and generative design.

The newsletter walks through the latest in PLMs, from EvolutionaryScale (recently acquired by CZI for its Biohub project) to companies like Profluent, which is using PLMs to design new CRISPR tools, and Cradle, where R&D teams can upload their lab data and get custom protein design models fine-tuned to their specific projects. 

There’s also a helpful breakdown of the challenges, like the fact that most PLMs treat proteins as static, even though proteins are anything but...

Anyway, check it out, you're following the AI x biology space (paywalled content).

Kudos to Roman Kasianov and the BioPharmaTrend.com team for exploring this topic!

Image credit: BiopharmaTrend

Wow, over €1.1 billion in biotech venture funds closed this week to support European biotech startups!  

Two new funds just announced:

🔹 Sofinnova Partners closed Capital XI at €650M, above its €500M target and €600M cap. The fund will focus on seed and Series A biotech and medtech companies, with areas like oncology, immunology, CNS, and cardio-metabolic diseases. 

They've already made five investments, including HAYA Therapeutics (RNA platform for cardiometabolic disease) and Galvanize (pulsed electric field for solid tumors).

🔹 Medicxi closed Fund V at €500M. It’s stage-agnostic, backing both newcos and more developed biopharma companies. Since its last fund in 2023, they’ve launched 16 companies and seen exits like Merus N.V. (€8B M&A) and ProfoundBio (both acquired by Genmab).

That’s a big chunk of new capital aimed at early science and drug development, with a decent spread across Europe, the UK, and the US.

Feels like momentum is building again in European biotech lately, at least at the fund level... 

This post is from a market analytics brief I did on European biotechs - for the upcoming article about the European life sciences community and growing hubs (hope to publish it in the coming days). 

If you are interested in the topic, follow me or subscribe to The Biotech Edge newsletter in the profile above. 

Image credit: Sofinnova Partners

BREAKTHROUGH ALERT: 
First 3D-printed, lab-grown cornea implanted in a human patient 👁️ 

As Fierce Biotech reports, Precise Bio has completed the first successful human implantation of a 3D-printed corneal graft constructed entirely from lab-grown human eye cells.

⚠️ Precise Bio’s technology addresses a significant unmet need: globally, only 1 cornea is available for every 70 patients in need of a transplant. 

The implant, called PB-001, was fabricated using Precise Bio’s robotic bio-fabrication platform, which combines cell biology, biomaterials engineering, and 3D bioprinting to replicate the native architecture of the cornea. 

As Conor Hale reports, unlike traditional transplants, which rely on donor tissue, PB-001 is derived from cultured human corneal cells and built to match the optical clarity, transparency, and biomechanical properties of a natural cornea.

The transplant was performed on October 29, 2025, in one eye of a blind patient. The procedure marks the first time scientists have integrated a fully lab-manufactured human corneal implant into a living patient. 

According to the company, the graft had previously undergone successful preclinical testing in animal models. 

Their platform aims to scale production by potentially generating hundreds of grafts from a single donor source through expansion and tissue engineering.

Technically, PB-001 is delivered preloaded on standard ophthalmic surgical devices and is cryopreserved for long-term storage and global distribution. 

During surgery, it unrolls into its natural shape, facilitating integration with host tissue using existing ophthalmic surgical workflows.

Dr. Michael Mimouni of Rambam Medical Center, who performed the procedure, stated that this development could mitigate the global shortage of donor tissue. 

Co-founders Aryeh Batt and Anthony Atala, said in a press release that PB-001 could potentially standardize corneal transplantation and offer a scalable alternative to current donor-dependent models.

Congrats to the team! 

🫡 Follow me for weekly insights about cutting-edge tech in the life sciences. 

Image credit: Fierce Biotech

Well, if Bruce Booth (Atlas Ventures) works just a little bit harder, everyone else in pharma analytics can just resign 😁. JK, but seriously, a cool report.  

I just finished watching it on YouTube (around 50min), and this year Bruce put an unusually sharp focus on politics. Well, maybe expected, the policy backdrop is chaotic, and it matters. From Trump’s tariff-driven manufacturing push, to unpredictable executive orders, to ca. 20% FDA staff turnover and leadership churn... this is no longer noise around the edges so to speak. It’s directly impacting timelines, sourcing strategies, and investor confidence. The NIH faces political pressure. Antivax rhetoric may be a concern for policymaking... And yet, the sector continues to adapt (what choice does it have anyway?).

There is too much insight to pack in one post, but let me highlight a couple that are more interesting to me: 

1. Patent expirations are the gravity pulling a lot of stuff.

Over the next five years, $40–45B annually in branded pharma revenue will go generic annually, a number triple the recent average! This is not a future problem. It’s a "now" problem. It means big pharma needs to replace 8–10 blockbuster drugs per year, and internal pipelines aren’t enough. That demand is fueling a surge in BD, early licensing, and risk tolerance for preclinical bets, especially for anything that can move quickly to POC.

2. The industry is saturated with programs targeting the same mechanisms

Bruce points out that 36 targets have 50+ active programs globally. Time from first to third-in-class approval has collapsed from 15 years to under 2. If you're in a hot space (e.g. GLP-1s, KRAS, ADCs), you're not just competing on science, you're competing on time-to-market and capital velocity. This is eroding value for all but the clear best-in-class or first-to-market entrants. And it means good science isn't enough anymore, you need strategic clarity on why your program deserves to exist.

3. Tx modalities are maturing, and that means consequences...

The industry spent the last decade chasing "platform promise." Now, it’s paying the price. Gene therapy, gene editing, molecular glues, many are delivering real signals, but safety events, CMC complexity, and unclear commercial models have sobered expectations. Bruce notes two dozen deaths tied to systemic gene therapies and gene editing trials, for instance... 

“These are working in patients. But they’re not without their challenges…” as Bruce remarks in conclusion. 

I linked the report in the comments, absolutely watch it, IMO it is the best time/value ratio piece of content about the pharma industry you can find for free.  

Image credit: Bruce Booth, Atlas Ventures

Partner at Atlas Venture

Ifra Saifi

Excited to see BioPharmaTrend.com cited in Ernst & Young (EY)’s latest report, “How Emerging Technologies Are Enabling the Human-Machine Hybrid Economy” — part of their new EY Megatrends series.

This in-depth piece explores how AI, robotics, brain-computer interfaces, and longevity research are accelerating us toward a hybrid era, one where human-machine collaboration pushes performance far beyond biological limits.

🔍 Key insights directly from the report:

Enhanced workforces deliver 2.4× better performance, but leaders must address widening cognitive and physical divides.

A study by MIT and Johns Hopkins involving 2,310 participants found that human-AI teams had 73% higher productivity and created higher-quality marketing content.

In manufacturing, exoskeleton-supported workers experienced up to 60% less physical strain, while industry-wide implementations saw 20–60% injury reductions and 15–25% productivity gains.

In healthcare, AI-assisted diagnostics increased fracture detection sensitivity from 72% to 80%, and specificity from 81% to 85%, while cutting diagnostic time by 30.8%.

In law, AI-powered contract review achieved 98% accuracy and cut review time from 92 minutes to 26 seconds.

Investment in longevity research reached $8.5 billion in 2024, a 220% increase over the previous year, reflecting growing interest in technologies that may extend productive working lives.

The article highlights urgent ethical and policy questions, including neural data privacy, cognitive autonomy, and the risk of an enhancement divide between those with access to augmentation and those without.


Kudos to Beatriz Sanz Saiz for highlighting not just the tech, but the ethical, strategic, and societal shifts leaders need to navigate! 

It is a thought-provoking, even entertaining, and insightful weekend read, folks. 

Image credit: Ernst & Young

taplio

Andrii Buvailo, Ph.D.'s Linkedin Analytics

Andrii Buvailo, Ph.D.

Performance ScoreAndrii Buvailo, Ph.D.'s LinkedIn Performance

Andrii Buvailo, Ph.D.'s Best Posts (last 30 days)

Ready to grow your LinkedIn presence?

taplio

.css-6ytdur{background-image:linear-gradient(284deg, rgba(39, 43, 72, 1) 0%, rgba(33, 47, 183, 1) 100%);color:transparent;-webkit-background-clip:text;background-clip:text;}Andrii Buvailo, Ph.D.'s Linkedin Analytics

Andrii Buvailo, Ph.D.

Performance Score.css-goub6s{font-size:var(--chakra-fontSizes-md);font-weight:500;color:var(--chakra-colors-gray-600);display:block;margin-top:var(--chakra-space-1);}Andrii Buvailo, Ph.D.'s LinkedIn Performance

Andrii Buvailo, Ph.D.'s Best Posts .css-1emoo84{font-size:var(--chakra-fontSizes-md);font-weight:400;color:var(--chakra-colors-gray-600);}(last 30 days)

Ready to grow your LinkedIn presence?

Andrii Buvailo, Ph.D.'s Linkedin Analytics

Performance ScoreAndrii Buvailo, Ph.D.'s LinkedIn Performance

Andrii Buvailo, Ph.D.'s Best Posts (last 30 days)